LUGPA Annual Meeting | Conference

Dr Henderson on Incorporating Immunotherapy Agents into Practice in Bladder Cancer

November 6th 2023

R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.

Dr Lowentritt on the Exploration of Active Surveillance in Prostate Cancer

November 6th 2023

Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.

Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate Cancer

November 3rd 2023

David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.

Dr Crawford on the Evolving Role of Active Surveillance in Prostate Cancer

November 3rd 2023

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

Role of Radiation Continues to Grow in the Treatment of Prostate Cancer

November 3rd 2023

Improved toxicity, advanced technology, and novel techniques have helped increase the use of radiotherapy for the treatment of different subgroups of patients with prostate cancer.

Strategic Active Surveillance Methods Drive Patient-Focused Prostate Cancer Care

November 3rd 2023

Active surveillance can provide eligible patients with low-risk prostate cancer the opportunity to defer or avoid treatment and instead opt for routine monitoring of their disease; however, challenges arise when determining which patients should be eligible for this approach and how to maintain patient and provider protocol compliance.

Genomics Help Drive Active Surveillance Decisions in Low-Risk Prostate Cancer

November 3rd 2023

David Morris, MD, FACS, discusses the increasing the use of active surveillance in patients with low-risk prostate cancer and the goals of avoiding adverse effects associated with possible therapies.

Dr Jayram on the Role of Immunotherapy in Bladder Cancer

November 3rd 2023

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Bladder Cancer Programs Offer Patients Comprehensive and Cutting-Edge Care

November 3rd 2023

Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.

Successful Bladder Cancer Programs Rely on Old Pillars, New Innovations

November 2nd 2023

Building a successful bladder cancer program requires clinicians to employ a multifaceted approach that prioritizes good surgical practices, embraces immunotherapies with an understanding of the adverse effects that can accompany them, and being up to date in terms of options for patients.

Dr Spratt on Sequencing Radiation Therapy and Hormone Therapy in Prostate Cancer

November 2nd 2023

Daniel Spratt, MD, discusses research findings that have delineated the optimal sequencing of radiation therapy and hormone therapy for patients with prostate cancer.

Ongoing Research Aims to Enhance Radiotherapy Techniques in Prostate Cancer

November 2nd 2023

Daniel Spratt, MD, discusses the expanded role of radiation therapy for the treatment of patients with prostate cancer, delves into the optimal approach for using radiation in tandem with hormonal therapy for these patients, and highlights ongoing research focused on minimizing adverse effects associated with radiotherapy.

Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer

November 14th 2022

Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.

Dr. Siefker-Radtke on Unmet Needs in Frontline Urothelial Cancer Treatment

November 14th 2022

Arlene O. Siefker-Radtke, MD, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma treatment.

Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing

November 12th 2022

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

Sequencing Considerations in mCRPC Treatment Grow Increasingly Complex

November 11th 2022

For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.

Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer

November 11th 2022

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

ADT Alone, With Docetaxel Is Not Enough: ADT Intensification Is SOC for Metastatic Castration-sensitive Prostate Cancer

November 11th 2022

Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.

Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

November 11th 2022

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC

November 11th 2022

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.